Fortrea Holdings Inc. (FTRE) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Fortrea Holdings Inc. (FTRE) Healthcare & Pipeline Overview

Fortrea Holdings Inc. is a global contract research organization specializing in biopharmaceutical and medical device development. Operating through Clinical Services and Enabling Services segments, Fortrea offers full-service and functional service provider models to pharmaceutical, biotechnology, and medical device organizations, focusing on streamlining clinical trials and optimizing drug supply processes.

What Is the Investment Thesis for FTRE?

Fortrea Holdings Inc. presents a notable research candidate within the contract research organization (CRO) sector. The company's focus on providing comprehensive clinical and enabling services to pharmaceutical, biotechnology, and medical device organizations positions it to capitalize on the growing demand for outsourced research and development. With a market capitalization of $1.73B, Fortrea's growth potential is underpinned by its ability to streamline clinical trials and optimize drug supply processes. Key value drivers include expanding its service offerings, penetrating new geographic markets, and leveraging technology to enhance trial efficiency. However, the company's negative profit margin of -16.5% and high beta of 1.77 indicate potential volatility and financial challenges. Investors should monitor the company's ability to improve profitability and manage its financial risks while capitalizing on growth opportunities within the expanding CRO market.

Based on FMP financials and quantitative analysis

FTRE Key Highlights

Fortrea Holdings Inc. operates as a contract research organization, providing biopharmaceutical and medical device development services.

• The company is structured into two segments: Clinical Services and Enabling Services.
• Fortrea offers various delivery models, including full service, functional service provider, and hybrid service structures.
• The company serves pharmaceutical, biotechnology, and medical device organizations.
• Fortrea's market capitalization is $0.98 billion, with a profit margin of -16.5% and a gross margin of 16.0%.

Who Are FTRE's Competitors?

FTRE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are FTRE's Key Strengths?

Comprehensive service offerings across the clinical development spectrum.

• Technology-enabled trial solutions.
• Flexible delivery models (full service, FSP, hybrid).
• Established relationships with pharmaceutical, biotechnology, and medical device organizations.

What Are FTRE's Weaknesses?

Negative profit margin (-16.5%).

• High beta (1.77) indicating higher volatility.
• Relatively new company (incorporated in 2023).
• Dependence on the biopharmaceutical and medical device industries.

What Could Drive FTRE Stock Higher?

Expansion into new geographic markets, particularly in Asia-Pacific and Latin America.

• Launch of new technology-enabled clinical trial solutions.
• Strategic partnerships and acquisitions to expand service offerings.
• Increased demand for outsourced clinical research services from pharmaceutical and biotechnology companies.

What Are the Key Risks for FTRE?

Financial-distress signal — its Altman Z-Score of 0.70 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-79.1%) — the business is not currently generating profit on shareholder capital.
• Intense competition in the CRO market could lead to pricing pressures and reduced profitability.
• Regulatory changes and compliance requirements could increase operating costs and complexity.
• Economic downturns could affect R&D spending by pharmaceutical and biotechnology companies.
• Dependence on key clients and contracts could pose a risk if those relationships are disrupted.
• Negative profit margin may deter investors.

What Are the Growth Opportunities for FTRE?

• Expansion of Clinical Services: Fortrea has the opportunity to expand its Clinical Services segment by offering specialized services in emerging therapeutic areas such as gene therapy and personalized medicine. The market for these specialized services is growing rapidly, with projections estimating a market size of $50 billion by 2030. By investing in expertise and infrastructure in these areas, Fortrea can attract new clients and increase its market share. This expansion can be achieved through strategic partnerships, acquisitions, and internal investments in research and development.
• Penetration of Emerging Markets: Fortrea can drive growth by expanding its presence in emerging markets such as Asia-Pacific and Latin America. These regions are experiencing rapid growth in healthcare spending and clinical trial activity, presenting significant opportunities for CROs. The market size in these regions is projected to reach $30 billion by 2028. By establishing local offices, building relationships with key stakeholders, and adapting its service offerings to meet local needs, Fortrea can capitalize on the growth potential in these emerging markets.
• Leveraging Technology for Trial Efficiency: Fortrea can enhance its competitive advantage by leveraging technology to improve the efficiency and effectiveness of clinical trials. This includes investing in advanced data analytics, artificial intelligence, and digital health solutions. The market for technology-enabled clinical trial solutions is growing rapidly, with projections estimating a market size of $20 billion by 2027. By adopting these technologies, Fortrea can reduce trial costs, accelerate timelines, and improve patient outcomes, attracting more clients and increasing its market share.
• Strategic Partnerships and Acquisitions: Fortrea can pursue strategic partnerships and acquisitions to expand its service offerings, geographic reach, and technological capabilities. This includes partnering with or acquiring companies that specialize in complementary services such as data management, regulatory affairs, and market access. By expanding its capabilities through partnerships and acquisitions, Fortrea can offer a more comprehensive suite of services to its clients, increasing its value proposition and attracting more business.
• Focus on Post-Approval Services: Fortrea can drive growth by expanding its post-approval services, which include activities such as pharmacovigilance, market research, and patient support programs. The market for post-approval services is growing rapidly, with projections estimating a market size of $15 billion by 2026. By offering a comprehensive suite of post-approval services, Fortrea can help its clients maximize the value of their products and maintain a competitive edge in the market.

What Are FTRE's Competitive Advantages?

• Specialized expertise in clinical trial management.
• Technology-enabled trial solutions.
• Full-service and functional service provider models.
• Established relationships with pharmaceutical, biotechnology, and medical device organizations.

What Does FTRE Do?

Fortrea Holdings Inc., established in 2023 and headquartered in Durham, North Carolina, is a contract research organization (CRO) dedicated to providing comprehensive biopharmaceutical and medical device development services on a global scale. The company operates through two primary segments: Clinical Services and Enabling Services. The Clinical Services segment focuses on delivering expertise across the clinical pharmacology and clinical development spectrum, supporting clients from early-stage research through late-stage trials. The Enabling Services segment offers patient access and clinical trial technology solutions designed to streamline complex randomization processes and optimize the trial drug supply chain. Fortrea offers a range of delivery models, including full-service, functional service provider (FSP), and hybrid service structures, providing clients with flexibility and tailored solutions to meet their specific needs. The company’s service offerings encompass Phase I-IV clinical trial management, differentiated technology-enabled trial solutions, and post-approval services. Fortrea serves a diverse clientele, including pharmaceutical, biotechnology, and medical device organizations, supporting them in bringing innovative therapies and medical technologies to market. Since its inception, Fortrea has focused on leveraging its expertise and technology to enhance the efficiency and effectiveness of clinical trials, contributing to the advancement of healthcare worldwide.

What Products and Services Does FTRE Offer?

• Provide clinical pharmacology services.
• Offer clinical development services.
• Provide patient access solutions.
• Offer clinical trial technology solutions.
• Streamline randomization processes for clinical trials.
• Optimize the trial drug supply process.
• Offer full service, functional service provider, and hybrid service structures.
• Provide Phase I-IV clinical trial management.

How Does FTRE Make Money?

• Offers clinical services across the clinical development spectrum.
• Provides technology solutions to streamline clinical trials.
• Generates revenue through service contracts with pharmaceutical, biotechnology, and medical device organizations.

What Industry Does FTRE Operate In?

Fortrea Holdings Inc. operates within the global contract research organization (CRO) market, which is experiencing substantial growth driven by increasing R&D spending in the pharmaceutical and biotechnology sectors. The CRO industry is characterized by intense competition, with companies vying for market share by offering specialized services and leveraging technological advancements. Fortrea's position within this landscape is defined by its focus on providing comprehensive clinical and enabling services, catering to the diverse needs of pharmaceutical, biotechnology, and medical device organizations.

Who Are FTRE's Key Customers?

• Pharmaceutical organizations
• Biotechnology organizations
• Medical device organizations

Wall Street analysts project Fortrea Holdings Inc. revenue of about $2.66B for fiscal 2026, with EPS near $0.84. The estimate reflects 9 contributing analysts.

Quarterly Financial Performance: Fortrea Holdings Inc.

Revenue for Fortrea Holdings Inc. came in at $678.2M during Q2 2026, a 6.6% improvement versus the preceding quarter. The company recorded a net loss of $13.2M, with diluted EPS of $-0.14. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, FTRE averaged $-0.23 in diluted EPS.

FTRE Valuation & Market Position

With a $1.73B market cap, Fortrea Holdings Inc. sits in the small-cap segment of the market. Relative to its peer group, FTRE's quantitative score of 28/100 is below the peer average of 76/100.

Return on equity for Fortrea Holdings Inc. stands at -79.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -16.7%, showing how much profit it generates from its asset base. Its free cash flow yield is 11.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.95 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -28.2%, the inverse of the P/E and a quick read on earnings relative to price.

Fortrea Holdings Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 0.70 places it in the distress zone, a signal of elevated financial risk.

Fortrea Holdings Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 84.1% above estimates on average.

Company Profile

Fortrea Holdings Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Durham, US. The company is led by CEO Anshul Thakral. FTRE has traded publicly since 2023.

FTRE Financials

FTRE Latest News

FTRE Analyst Consensus

FTRE MoonshotScore

Fortrea Holdings Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources